Progressive Disease with Mixed Response After Immunotherapy in Non-Small Cell Lung Cancer
PDMR was primarily observed in stage IV patients and previously irradiated patients. OS and PFS were inferior in patients with PDMR compared to patients with PDNMR. The continuation of immunotherapy in PDMR patients could extend their survival.
Authors
- Ziyuan Ren (ORCID: https://orcid.org/0000-0002-0275-141X)
- Weiwei Yan (ORCID: https://orcid.org/0009-0009-2031-3067)
- Dawei Chen (ORCID: https://orcid.org/0000-0002-6762-7997)
- Xi Chen (ORCID: https://orcid.org/0000-0002-3013-4558)
- Ran Zhang (ORCID: https://orcid.org/0000-0003-3376-6945)
- Jinming Yu (ORCID: https://orcid.org/0000-0001-5933-9912)
- Juncai Lv
Institutions
- Shandong University (CN)
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Journal of Inflammation Research
- Published
- 2024-09-01
- DOI
- https://doi.org/10.2147/jir.s477244
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province